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ScienceDirectIntratumour heterogeneity complicates biomarker discovery
and treatment personalization, and pervasive cancer evolution
is a key mechanism leading to therapy failure and patient death.
Thus, understanding subclonal heterogeneity architectures
and cancer evolution processes is critical for the development
of effective therapeutic approaches which can control or thwart
cancer evolutionary plasticity. Current insights into
heterogeneity are mainly limited to the macroheterogeneity
level, established by cancer subclones that have undergone
significant clonal expansion. Novel single cell sequencing and
blood-based subclonal tracking technologies are enabling
detailed insights into microheterogeneity and the dynamics of
clonal evolution. We assess how this starts to delineate the
rules governing cancer evolution and novel angles for more
effective therapeutic intervention.
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Introduction
Cancer is a genetic and epigenetic disease arising from a
single cell that has acquired the hallmarks of cancer.
Although monoclonal in origin, the background mutation
rate and genomic instability mechanisms which are oper-
ative in many cancers foster the generation of new muta-
tions during the ensuing expansion of the cancer cell
population [1,2]. Although most new mutations are likely
to be deleterious or have no impact on cellular fitness, the
enormous number of mutations which can be generated
during progression into an advanced cancer, harbouring
up to hundreds of billions of malignant cells [3], likely
generates a wealth of viable phenotypes. This subclonal
diversity is the substrate which Darwinian selection can
act upon, permitting the on-going evolutionary adaptationwww.sciencedirect.com of cancer populations through the expansion of subclones
harbouring beneficial aberrations [4].
However, new mutations, bestowing genetic diversity,
are initially confined to individual cells and to small
subclones after subsequent rounds of cell division. These
remain below the detection limit of standard exome or
genome sequencing approaches, which have low sensi-
tivity and high false positive rates when applied for the
detection of mutations with allele frequencies below 10%
in the DNA extracted from a tumour sample [5]. Thus,
this microheterogeneity remains undetectable until a
significant expansion of one or more subclones establishes
macroheterogeneity (Figure 1a), which may have a
branched evolutionary pattern (Figure 1b). Novel single
cell [6,7,8] and ultra-deep DNA sequencing technolo-
gies [9] only recently started to permit investigations into
intratumour micro-heterogeneity and macro-heterogene-
ity, whilst circulating tumour DNA (ctDNA) detection
techniques [10–13] and circulating tumour cell molecular
analyses [14] provide insight into the dynamics of evolu-
tionary adaptation. We review how these techniques
reveal intratumour micro-heterogeneity and macro-het-
erogeneity, thereby unravelling the fundamental evolu-
tionary nature of cancer and the central role of genetic
intratumour heterogeneity for patient outcome.
Evidence for intratumour macroheterogeneity
Intratumour macroheterogeneity has been observed
across several solid tumour types. Exome sequencing
of multiple tumour regions from ten clear cell renal cell
carcinomas (ccRCC) demonstrated that, on average, over
two thirds of driver somatic copy number aberrations
(SCNAs) and of driver mutations were heterogeneous
within individual tumours [15]. Subclones were spatial-
ly demarcated within primary tumours and differed be-
tween primary tumours and metastatic sites within
patients. Reconstructing the ancestral relationships of
these subclones revealed branched evolutionary patterns
with multiple subclones evolving simultaneously in each
tumour but along distinct evolutionary paths [15]. A
characteristic found in all ten tumours was the presence of
inactivating somatic alterations in the von Hippel Lindau
(VHL) gene and loss of heterozygosity of chromosome 3p,
harbouring the second copy of the VHL gene, on the trunk
of the phylogenetic trees. Thus, these driver aberrations
had been acquired early, most likely in the founding cell
of each tumour. In contrast, other known ccRCC driver
genes, including PI3K-mTOR pathway genes and
those encoding epigenetic regulators were predominantlyCurrent Opinion in Genetics & Development 2015, 30:1–6
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Macro and microheterogeneity in cancer evolution. (a) Schematic
illustrating clonal evolution. Multiple subclones evolve from the
founding clone (blue) and undergo major clonal expansions, changing
the composition of the tumour cell population. Subclones are
detectable as macroheterogeneity by standard next generation
sequencing approaches owing to their large population sizes.
Magnifications of small proportions of the cancer cell population
(insets) show the population structure at the microheterogeneity level.
Newly generated mutations in single cells, which subsequently expand
into small subclonal populations are below the detection limit of
standard next-generation sequencing techniques and can only be
detected through single cell or ultra-deep sequencing technologies. (b)
Phylogenetic tree reconstructed from the macroheterogeneity data,
depicting a branched evolutionary trajectory. The founding clone (blue)
represents the trunk of the phylogenetic tree.mutated in tumour subclones. SETD2, BAP1 and PBRM1
driver gene mutations were found in distinct subclones
within the same tumour, defying that mutations in these
genes define distinct molecular ccRCC subtypes [15].
Studies into signalling pathway activity and prognostic
and predictive biomarker expression demonstrated thatCurrent Opinion in Genetics & Development 2015, 30:1–6 genetic heterogeneity was associated with phenotypic
diversity [15,16,17]. Multi-region exome sequencing
of high-grade serous ovarian cancers also found macro-
heterogeneity and branched evolution, with early truncal
TP53 mutations in five out of six patients, whereas driver
genes such as PIK3CA, CTNNB1 and NF1 were mutated
in subclones [18]. Multi-region SCNA profiling of nine
glioblastomas demonstrated homogenous CDKN2A/B
losses and EGFR amplifications, suggesting early acqui-
sition on the trunk of the phylogenetic trees [19]. In
contrast, SCNAs harbouring RB1, AKT3, and MDM4 were
always found to be subclonal whereas those affecting
CDK6, MET, PDGFRA, PTEN and TP53 were subclonal
in some and truncal in other cases [19].
Evidence for macroheterogeneity with significantly ex-
panded subclones has also been identified within individ-
ual cancer samples. Deep sequencing of triple negative
breast cancer biopsies revealed that most TP53, PIK3CA,
and PTEN mutations had been acquired early during
tumour evolution although they were subclonal in a small
proportion of cases [20]. In contrast, mutations in
cytoskeletal, cell shape and motility proteins were pre-
dominantly subclonal, suggesting on-going evolutionary
adaptation. Fluorescence in situ hybridisation of driver
SCNAs identified genetically distinct subclonal popula-
tions in the majority of ETV6-RUNX1 positive acute
lymphoblastic leukaemias (ALL) [21]. Twenty-four cases
exhibited branched evolution and only six malignancies
followed a linear evolutionary pattern [21]. Sequencing of
single biopsies from non-small cell lung cancers
(NSCLC) revealed subclonal heterogeneity in ten out
of 17 cases [22]. Tumours harbouring KRAS or EGFR
mutations had always acquired these in the founding
clone, whereas putative driver mutations in HGF were
subclonal. A large study investigating mutation concor-
dance within NSCLC primary tumours and between
primary tumours and metastases or recurrences found
no macroheterogeneity of EGFR driver mutations, further
supporting the notion that activating EGFR mutations are
generally truncal [23]. This was also confirmed by two
recent NSCLC multi-region exome sequencing studies.
All identified activating EGFR mutations and indeed the
majority of all other known NSCLC driver mutations and
driver SCNAs were located on the trunks of the phyloge-
netic trees [24,25]. Macroheterogeneity and branched
phylogenetic patterns were nevertheless identified in
each tumour. Although most heterogeneous aberrations
may be passengers, the high mutation rate in NSCLCs
impairs the ability to define the driver gene catalogue of
these tumours [26] and subclonal drivers may have
remained undetected as a consequence. Mutational sig-
nature analysis showed that a cell-endogenous mutational
process caused by up-regulation of the APOBEC deami-
nase [24,25] was the predominant mechanism of NSCLC
subclonal mutation generation [27], even in patients
with on-going tobacco smoke exposure.www.sciencedirect.com
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Novel sequencing technologies increasingly allow the
investigation of microheterogeneity at the fundamental
level of the single cell. The detection of SCNAs and point
mutations in up to 60 individual cell nuclei from each of
two breast cancers identified major subclones evolving in
a branched evolutionary fashion in each tumour [8],
corroborating the conclusion from breast cancer macro-
heterogeneity studies [20]. Single cell resolution further
revealed relatively stable SCNA profiles across cancer
cells within a tumour whereas point mutations differed
between major subclonal populations but also within
subclones. Thus, SCNAs had been acquired early during
carcinogenesis and point mutation acquisition was con-
tinuously driving microheterogeneity generation. Muta-
tion rate estimates based on this data revealed 8 new
mutations per cell division in a triple negative cancer and
0.6–0.9 new mutations in an ER positive tumour, which is
similar to the estimated 0.6 new mutations per division for
normal cells. Importantly, single cell mutational hetero-
geneity allows insights into current mutation rates. In
contrast, mutations observed at the macroheterogeneity
level have been acquired many generations before clonal
expansion made them detectable and only provides a
historical record of the mutational processes that were
operative in earlier tumour stages [28].
Reconstruction of SCNA profiles from single cell RNA
sequencing data from glioblastomas identified a mono-
clonal structure in four cases and two major subclones
within one further case [29]. Within the limits of the
assay, which has a low sensitivity to detect small aberra-
tions, SCNAs were similar between individual cells of a
clone or subclone. Thus, the generation of new SCNAs
may be a rare event and the observed profiles were likely
acquired early during cancer evolution, similar to the
results in breast cancers [8]. Single cell RNA expression
data further enabled the simultaneous assessment of gene
expression profiles between single cells with similar
SCNA profiles. This detected transcriptional signatures
of different glioblastoma subtypes and variable degrees of
stemness co-existing in different cells within a tumour.
The simultaneous interrogation of genetic and non-
genetic macroheterogeneity within a cancer cell popula-
tion provides powerful opportunities to assess phenotypic
consequences of subclonal genetic aberrations.
Macroheterogeneity of known driver mutations is rare
between primary colorectal cancers (CRCs) and associat-
ed metastatic lesions. Mutations in KRAS, NRAS, BRAF
and APC driver genes were always concordant and only
low-level discordance was observed for mutations in
TP53, PIK3CA and PTEN in a study of 69 primary
CRC and metastasis pairs [30]. The absence of macro-
heterogeneity, for example for KRAS and NRAS muta-
tions, suggests that these drivers were acquired on the
trunk of the phylogenetic tree, in tumours in which theywww.sciencedirect.com are detectable. The high concordance most likely
explains the robust performance of KRAS and NRAS
mutations as predictors of primary resistance to anti-
EGFR therapy in CRCs [31,32]. However, KRAS and
NRAS mutations became detectable in the ctDNA from
23 out of 24 initially KRAS/NRAS wild-type CRCs at the
time acquired resistance to anti-EGFR treatment had
developed [33]. Surprisingly, multiple distinct activat-
ing KRAS and NRAS mutations emerged in the ctDNA in
63% of patients, demonstrating that polyclonal resistance
evolution was common. An analysis of the kinetics of
KRAS mutation evolution in these patients further con-
cluded that KRAS mutations had been present before
anti-EGFR therapy initiation, in small subclones com-
prising 2000–3000 cancer cells [34]. Direct support for
this microheterogeneity has been provided by the detec-
tion of low level KRAS mutations by sensitive digital PCR
technology in patients found to be KRAS wild-type by
standard detection techniques [41]. Thus, microhetero-
geneity of KRAS mutations and potentially also of other
resistance driver mutations is likely to be present in many
metastatic CRCs which are KRAS wild-type based on
standard sequencing approaches. These mutations may
evade detection owing to the small number of affected
cells and through spatial segregation across metastatic
sites but they eventually drive resistance evolution and
therapy failure. The reliable evolution of one or multiple
KRAS or NRAS mutant subclones in most patients during
anti-EGFR therapy further suggest that the population
size and mutation rates are sufficiently high to generate
many beneficial driver mutations in any metastatic CRC.
The presence of KRAS mutation microheterogeneity in
many tumours which are KRAS wild-type by standard
sequencing technologies together with the absence of
KRAS mutational macroheterogeneity further indicated
that these new subclones rarely undergo significant clonal
expansion. Thus, KRAS mutations apparently have a low
or no selective advantage unless they are acquired early
during carcinogenesis or the tumour is treated with
EGFR-targeted agents.
The presence of strong driver aberrations in the founding
cell of most CRCs which leaves only limited opportunity
to further optimize cancer cell fitness could be a parsimo-
nious explanation for this paradox. In other words, many
CRCs may already occupy a fitness peak on the fitness
landscape at the time of cancer initiation (Figure 2a)
precluding significant expansion and macroheterogeneity
evolution of subclones harbouring additional drivers. This
may be fundamentally different in the founding cell of a
ccRCC (Figure 2b), which may only harbour a small
number of weak drivers such as mutations in VHL and
chromosome 3p loss. This is supported by studies in
patients with germ-line VHL mutations which only
showed a modest proliferative advantage of biallelic
VHL inactivation in renal tubular cells [35] compared
to the proliferative advantage conferred by biallelicCurrent Opinion in Genetics & Development 2015, 30:1–6
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Influence of the fitness landscape on cancer evolutionary patterns. (a)
Hypothetical cancer fitness landscape in which the founding cell (red
dot) is already located at a fitness peak. Further evolutionary
adaptation is only possible through a change in the fitness landscape,
for example through a change in the environment or through drug
therapy. Microheterogeneity can be extensive in this tumour but
macroheterogeneity is absent. (b) Hypothetical fitness landscape
where the founding cell is not located at a fitness peak. Tumour
subclones can increase their relative fitness through the acquisition of
further driver mutations which will lead to subclonal expansion.
Increases in fitness are illustrated as arrows climbing up the fitness
peaks. If multiple subclones acquire drivers that increase their relative
fitness, branched evolution can occur. Multiple fitness peaks indicate
multiple possible phenotypes which lead to increased cellular fitness.inactivation of the APC tumour suppressor gene (which is
altered in 80% of CRCs [36]) in colon cells. Thus, the
founder clone of a typical ccRCC is likely to be located on
a fitness landscape that permits significant further fitness
increments through the acquisition of additional driver
aberrations (Figure 2b). This would explain the frequent
evolution of subclones harbouring additional driver
genes and the detection of macroheterogeneity in these
tumours.
Conclusions
Exome and genome sequencing studies of up to 500 can-
cer samples recently identified the most prevalent driver
genes in many cancer types. In parallel, smaller studiesCurrent Opinion in Genetics & Development 2015, 30:1–6 started to portray the subclonal landscapes of many tu-
mour types at the macroheterogeneity level through
multi-region sequencing approaches or subclonal compo-
sition analysis of individual biopsies. This provided am-
ple evidence for on-going evolutionary adaptation during
cancer progression, frequently along complex branched
trajectories, and started to delineate the spatial structures
of subclonal architectures. The spatial segregation of
functionally distinct subclones is a major hurdle for per-
sonalized cancer therapies as it complicates efforts to
accurately assess the driver aberration landscapes of in-
dividual tumours. These results also question whether
and how tumours harbouring subclones with different
driver mutations can be optimally treated. The concept of
a clinically dominant clone, which is not necessarily
numerically dominant in a cancer but ultimately lethal
for an individual patient [37,38], is emerging from this
work and the development of strategies to detect, track
and treat clinically dominant subclones is an important
area of future research. At the same time, macroheter-
ogeneity studies started to define cancer type specific
‘evolutionary rules’, such as the identification of driver
genes which are commonly altered on the trunk of a
specific tumour type, providing opportunities to prioritize
the development of targeted therapeutics [39]. Most
recently, new technologies enabled the study of micro-
heterogeneity in exceedingly small subclones and even at
the quantum level of the single cell. Combined with
assessments of subclonal population dynamics through
ctDNA or circulating tumour cell tracking [14], these
tools start to unravel key mechanisms of cancer evolution
at an unprecedented level of detail. For example, quan-
tification of de novo mutation generation, the construc-
tion of genotype-phenotype maps and ultimately the
mapping of dynamic fitness landscapes can now be ac-
complished. As on-going cancer evolution fosters cancer
progression and therapy failure [40], a fundamental un-
derstanding of the rules governing cancer evolution may
lead to novel therapeutic and preventive approaches to
slow down or thwart evolution in order to improve clinical
outcomes.
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